Stay updated on Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added. The funding-lapse notice and the prior revision (v3.4.1) were removed.SummaryDifference0.5%

- Check21 days agoChange DetectedSite-wide updates include a government funding status notice and a Revision: v3.4.1, along with the removal of the previous Revision: v3.4.0; these changes do not alter the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a glossary toggle to the page and updated QC-related metadata in the Study Record Dates and footer. The previous QC label and older footer phrasing were removed or changed, reflecting a minor metadata/update change.SummaryDifference0.2%

- Check35 days agoChange DetectedA new page revision label (v3.3.4) was added and the previous revision (v3.3.3) was removed; this appears to be a minor metadata update with no visible impact on the study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedFooter now shows 'Revision: v3.3.3'. The 'HHS Vulnerability Disclosure' link and the 'Revision: v3.3.2' entry were removed.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page revision label updated from v3.3.1 to v3.3.2, indicating a minor page update. No substantive trial content appears to have changed.SummaryDifference0.1%

Stay in the know with updates to Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.